Showing 3101-3110 of 5771 results for "".
- LEP Biomedical Closes Pre-Seed Funding to Advance HyaGuard Platformhttps://modernod.com/news/lep-biomedical-closes-pre-seed-funding-to-advance-hyaguard-platform/2482243/LEP Biomedical announced pre-seed funding of €100,000 ($107,000) over two 6-month periods, which the company says will allow for further preclinical milestones in the development of the HyaGuard platform. The funding was made through Enterprise Ireland. Accordin
- DigitalOptometrics Surpasses 2 Million Remote Eye Examshttps://modernod.com/news/digitaloptometrics-surpasses-2-million-remote-eye-exams/2482242/DigitalOptometrics announced it has surpassed 2 million remote comprehensive eye exams. DigitalOptometrics' remote eye exam platform is designed to allow optometrists to conduct comprehensive eye exams remotely, integrating video conferencing with remote operation of opht
- BVI’s Podeye Hydrophobic Monofocal IOL Launched in Japanhttps://modernod.com/news/bvis-podeye-hydrophobic-monofocal-iol-launched-in-japan/2482239/BVI Medical announced the launch of the Podeye hydrophobic monofocal intraocular lenses (IOL) in Japan after receiving approval by the Japanese Pharmaceuticals and Medical Devices Agency. Podeye is now available for commercial use and available to surgeons across the country. The Podeye
- Ocugen Completes Dosing in Phase 1/2 Trial of OCU410 for Geographic Atrophyhttps://modernod.com/news/ocugen-advances-armada-trial-of-ocu410-to-treat-patients-with-geographic-atrophy/2482238/Ocugen announced dosing is complete in the second cohort of its phase 1/2 ArMaDa trial of OCU410, an adeno-associated viral vector 5 human RORA (AAV5-hRORA) gene therapy being developed for geographic atrophy (GA). Up to 13
- Ocular Therapeutix Releases Topline Results for Phase 1 Trial of Axpaxli for Diabetic Retinopathyhttps://modernod.com/news/ocular-therapeutix-axpaxli-in-diabetic-retinopathy-evaluated-in-phase-1-helios-clinical-trial/2482237/Ocular Therapeutix announced positive topline results from the phase 1 HELIOS study, which is evaluating the safety, tolerability, and efficacy of drug candidate Axpaxli versus a sham control in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) without di
- Aqueous Humor Proteome Database Established by Medical College of Georgiahttps://modernod.com/news/aqueous-humor-proteome-database-established-by-medical-college-of-georgia/2482236/The National Eye Institute (NEI) recently announced a database that will enable researchers to better study causes of vision loss has been established by scientists at the Medical College of Georgia (MCG) at Augusta University in Augusta, Georgia. The Aqueous Humor (AH) Proteome Databas
- Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovationhttps://modernod.com/news/regeneron-backs-500-million-venture-capital-fund-for-biotechnology-innovation/2482234/Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, MD, and Michael Aberman, M
- EyeSouth Partners Affiliates With Community Eye Care Specialists in New Yorkhttps://modernod.com/news/eyesouth-partners-affiliates-with-community-eye-care-specialists-in-new-york/2482233/EyeSouth Partners announced it has partnered with Community Eye Care Specialists, representing its first affiliation in New York, third affiliation in Pennsylvania. and 40th affiliation overall. Financial terms of the deal were not disclosed. EyeSouth is an eye care-focused ma
- In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streakshttps://modernod.com/news/in-japanese-study-vabysmo-achieves-primary-endpoint-in-phase-3-study-for-angioid-streaks/2482231/Japan-based Chugai Pharmaceutical announced that the Japanese phase 3 study (NIHONBASHI study), evaluating Roche and Genentech's Vabysmo (faricimab) for angioid streaks associated with neovascularization, met its primary endpoint, demonstrating statistically signific
- Ocular Therapeutix Names Pravin U. Dugel, MD, President and CEOhttps://modernod.com/news/ocular-therapeutix-names-pravin-u-dugel-md-president-and-ceo/2482230/Ocular Therapeutix announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer. Dr. Dugel, who will continue to serve as a director and as Executive Chairman of Ocular, is replacing Antony Mattessich, who is stepping down f